StreetAlpha.app
Home › Stocks › ABCL

AbCellera Biologics Inc. (ABCL)

Healthcare
$11.03
▼ −0.81%
LAST CLOSE · NOV 17

AbCellera discovers antibodies and develops them with pharmaceutical, biotechnology and nonprofit partners. It last closed at $11.03 on Nov 17, down 0.81% on the day. ABCL last reported earnings on Mon, Nov 9, 2026. The average 12-month price target from 6 analysts is $16.17 (+46.6% from the last close), with a high of $20.00 and a low of $13.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ABCL, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is ABCL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$67.9M
+92.1% vs a year ago
Net income
−$148.3M
−218.6% margin
EPS (diluted)
−$0.48
Free cash flow
−$32.9M
−48.4% margin
Valuation
Market cap
$3.6B
326.6M shares
P/E
–
No P/E while losing money
Price to sales
53.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$163.8M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
326.6M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $375.2M$375.2MFY2021FY2022: $485.4M$485.4MFY2022FY2023: $38.0M$38.0MFY2023FY2024: $28.8M$28.8MFY2024FY2025: $75.1M$75.1MFY2025

From ABCL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · After the close (AMC)
Reported EPS
-$0.13
vs -$0.18 est. · beat
Year-ago EPS
-$0.19
Same quarter last year
Options-implied move
±13.9%
Priced in before that report
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
5 Buy1 Hold0 Sell
Each firm's latest rating on ABCL in the past 90 days
Average 12-month target
$16.17
▲ 46.6% upside

Based on 6 analysts who set a price target on ABCL in the past 90 days. The average target is $16.17, with a high of $20.00 and a low of $13.00, compared with the last close of $11.03.

$4$10$15$21PAST 44 TRADING DAYS12-MONTH TARGETSHIGH $20AVG $16.17LOW $13May 22LAST CLOSE+12 MO$4$10$15$21PAST 44 DAYSTARGETSHIGH $20AVG $16.17LOW $13May 22LAST CLOSE+12 MO
Highest target$20.00
Average target$16.17
Lowest target$13.00
Latest rating changes
Piper SandlerMaintained
Nov 16Buy$20
StoneXMaintained
Nov 11Buy$15
StifelTarget raised
Nov 10Buy$9 → $14
UBSInitiated
Oct 12Buy$18
JP MorganInitiated
Sep 29Buy$17
DateFirmActionRatingPrice target
Nov 16Piper SandlerMaintainedBuy$20
Nov 11StoneXMaintainedBuy$15
Nov 10StifelTarget raisedBuy$9 → $14
Oct 12UBSInitiatedBuy$18
Sep 29JP MorganInitiatedBuy$17
Loading…

Technical Analysis

ABCL · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 9% below its 20 day and 12% below its 50 day average. It is 34% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Sep 2) at $10.80, and the nearest resistance the Pivot at $11.08.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 8.0%/day
Key levels
$15.0252 week high+36.2%
$12.3250 day average+11.7%
$12.0020 day average+8.8%
$11.82Swing high (Sep 3)+7.2%
$11.35Pivot R1+2.9%
$11.08Pivot+0.5%
$11.03Last close
$10.80Swing low (Sep 2)−2.1%
$10.76Pivot S1−2.4%
$10.41100 day average−5.6%
$7.31200 day average−33.7%
$2.7552 week low−75.1%
Indicators
RSI (14)42.26Middle of its rangeNeutral
MACD-0.25Below its signal lineBearish
Stochastic14.6Near the bottom of its rangeOversold
ADX (14)12.4No clear trend
Williams %R-91.3Oversold below −80, overbought above −20Oversold
CCI (20)-122.8Oversold below −100, overbought above 100Oversold
Rate of change−9.4%Change over 10 sessionsBearish
ATR (14)$0.89Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for ABCL

What happened before

See how ABCL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ABCL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ABCL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 23 – Sep 23
Loading…

See today’s whale options flow across the market →

ABCL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●89 buying vs 87 selling
  • ▲Held by funds +4.5 pts
  • ▲Funds holding +11
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding164153+7.2%
In funds' top 1021+100.0%
Held by funds40.2%35.7%+4.5 pts
New / increased44 / 4539 / 35+20.3%
Reduced / sold out55 / 3254 / 26+8.8%
Put/call ratio3.264.62−29.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ABCL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABCL is in one of them and how their past ABCL trades turned out.

ABCL in the AI portfolios
Loading…

ABCL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ABCL in an article yet. Here's the latest on the wider market.

About AbCellera Biologics

AbCellera is a biotechnology company based in Vancouver, British Columbia, Canada. It uses its antibody discovery and development platform to find antibodies that partners can turn into drug candidates. Its partners include pharmaceutical companies, biotechnology companies, and nonprofit and government organizations. AbCellera receives upfront payments for technology access and discovery research, and it may also receive milestone payments and royalties if partner drugs advance or sell.

Headquarters
Vancouver, British Columbia, Canada